Epalinges, Switzerland/Los Angeles, California (USA) – June 20, 2025 - ASPIVIX is pleased to announce a strategic distribution agreement with Titus Health Care to bring Carevix®, our innovative non-traumatic suction cervical stabilizer, to healthcare providers and patients in the Netherlands, Belgium and Luxembourg. This partnership marks another step forward in our mission to modernize gynecology with solutions that put women’s comfort and experience first.

Titus Health Care, based in the Netherlands, is a leading player in women’s health and fertility. Known for its strong clinical network and commitment to innovation, Titus is an ideal partner to expand access to Carevix®—our CE-marked device designed to reduce pain and bleeding during transcervical procedures, such as intra uterine device (IUD) placement.

Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30% to 45% of women globally, an estimated 120 million women each year, primarily due to the use of the traditional cervical tenaculum. In the ADVANCE Women Study, a single-blinded, randomized, multicenter comparative trial, Carevix® demonstrated a 73% reduction in pain and 78% reduction in bleeding during IUD placement compared to the standard tenaculum becoming a new alternative for better patient experience.

Joep de Mönnink, Founder & Director of Titus Health Care, shares “At Titus HealthCare, we are committed to offering solutions that truly improve the experience of women and their care providers. Carevix® represents an important step toward more respectful, pain-conscious gynecology. We’re excited to bring this innovation to the Netherlands and Belgium, empowering clinicians with tools that reflect the care women deserve.”

Mathieu Horras, ASPIVIX CEO & Co-Founder, adds “We’re proud to partner with TitusHealth Care, whose reputation and reach in the Benelux region will help accelerate access to Carevix®. Together, we’re enabling a shift toward gentler, more modern care, helping women make informed choices adopting IUD without the fear of pain and bleeding. ”
With this agreement, ASPIVIX reinforces its growing presence in Europe.
The launch of Carevix® in the Netherlands and Belgium marks a meaningful step forward in redefining gynecological procedures—from IUD insertions to IVF treatments—by putting patient comfort and dignity at the center of care.

Reference:
1. Michal Yaron, Hélène Legardeur, Bastien Barcellini, Farida Akhoundova, Patrice Mathevet, Safety and efficacy of a suction cervical stabilizer for IUD insertion: results from a randomized, controlled study, Contraception, 2023, 110004, ISSN 0010-7824, Contraception link